Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company that discovers and develops therapeutic products to treat and prevent serious infectious diseases. Its clinical pipeline includes investigational therapies targeting hepatitis delta virus (HDV) and solid tumors. Preclinical candidates focus on influenza A and B antibodies, antibody drug conjugates, and coronavirus monoclonal antibodies. The company also develops PRO-XTEN, a dual-masked TCEs targeting various solid tumors. Vir Biotechnology operates in the United States and globally, leveraging collaborations with partners such as Astellas, Alnylam Pharmaceuticals, and GlaxoSmithKline Biologicals.

Vir Biotechnology is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol VIR. Its shares are traded in US Dollars (USD), reflecting its primary listing in the United States.

Vir Biotechnology operates in the Healthcare sector and is classified under the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on discovering and developing innovative therapies for serious infectious diseases, which places it within the broader biotechnology field that involves using biological processes to create medical treatments.

Vir Biotechnology is headquartered in San Francisco, California, United States. The company serves markets both in the United States and globally, as indicated by its description of operating in the US and internationally. Its pipeline targets infectious diseases that affect patients worldwide, including hepatitis delta virus, influenza, and coronaviruses.

Vir Biotechnology has several significant collaborations and license agreements. It has a grant collaboration and license agreement with Astellas, a license agreement with Norgine for the treatment of chronic hepatitis D (CHD), and an amended letter agreement with the Gates Foundation. The company also holds an option and license agreement with Brii Biosciences, a collaboration with Alnylam Pharmaceuticals, and license agreements with the Institute for Research in Biomedicine, The Rockefeller University, and Xencor. Additionally, it has a collaborative research agreement with GlaxoSmithKline Biologicals S.A. These partnerships support the development of its pipeline candidates.